AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Autoimmune Disease Therapeutics Market by Drug Class, Indication, Sales Channel and Region - Forecast to 2025 - ResearchAndMarkets.com

October 23, 2019

DUBLIN--(BUSINESS WIRE)--Oct 23, 2019--

The “Autoimmune Disease Therapeutics Market by Drug Class, Indication and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025” report has been added to ResearchAndMarkets.com’s offering.

According to this report, the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.

The demand for autoimmune disease therapeutics is estimated to increase during the forecast period owing to surge in prevalence of autoimmune disease, advancement in screening & diagnosis procedures, and wide availability of advanced therapeutics. Moreover, strong presence of pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others is expected to further boost the market growth.

Based on drug class, the global autoimmune disease therapeutics market is segmented into anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the major revenue contributing segment in 2017, and is expected to maintain its dominance during the forecast period owing to increase in demand for anti- inflammatory drugs, launch of newer anti- inflammatory drugs with the supportive reimbursement policies for usage of advanced anti- inflammatory drugs in some countries. Moreover, expected launch of pipeline anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept, golimumab, and others, is estimated to further influence the market growth.

Based on indication, the market is classified as rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. Rheumatic disease segment accounted for a major share in 2017 and is expected to remain dominant during the forecast period owing to surge in prevalence of arthritis, fibromyalgia, systemic lupus erythematosus, gout, scleroderma, polymyalgia rheumatica and others, wide availability of advanced therapeutics for treatment of rheumatic disease, availability of advanced therapeutics for the treatment of these diseases.

According to sales channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online stores. Online providers segment is expected to experience rapid growth during the forecast period owing to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users. On the other side, drug store & retail pharmacy segment is estimated to be the major revenue contributor due to massive presence of these pharmacies.

North America accounted for a major market share in 2017, and is expected to remain dominant throughout the forecast period. Higher prevalence of autoimmune disease, early diagnosis, easy availability of advanced therapeutics, strong presence of key players, favorable reimbursement in healthcare system, and higher number of trained medical professionals are key drivers of the North America autoimmune disease therapeutics market.

On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period owing to increase in number of target population, rise in adoption of therapeutics with development in healthcare infrastructure.

Key Findings of the Autoimmune Disease Therapeutics Market

For more information about this report visit https://www.researchandmarkets.com/r/o7t6zp

View source version on businesswire.com:https://www.businesswire.com/news/home/20191023005316/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/23/2019 04:48 AM/DISC: 10/23/2019 04:48 AM

http://www.businesswire.com/news/home/20191023005316/en